Citations

Clear

988 citation(s) found for "Ansell, Stephen M".

Prevalence and Impact of Clonal Hematopoiesis in Therapy Related Myeloid Neoplasms Occurring in the Context of Low-Grade Follicular Lymphoma Treated with Radioisotope Therapy
Lasho, Terra, Khurana, Arushi , Finke, Christy M. , Mangaonkar, Abhishek A. , Ansell, Stephen M. , Al‐Kali, Aref , Gangat, Naseema , Abeykoon, Jithma P. , Patnaik, Mrinal M. , Xie, Zhuoer , Ferrer, Alejandro , Fernandez, Jenna , Shah, Meera , Witzig, Thomas E.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 11403-11405

10.1182/blood-2022-165124 Get It

Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome
Chohan, Karan , Zanwar, Saurabh , Thompson, Carrie A. , Chanan‐Khan, Asher , Ansell, Stephen M. , Kumar, Shaji , Pruthi, Rajiv K. , Nichols, William L., Kapoor, Prashant , Abeykoon, Jithma P. , Chohan, Karan L , Go, Ronald S. , Paludo, Jonas , Ailawadhi, Sikander , Habermann, Thomas M. , Witzig, Thomas E. , Gertz, Morie A. , Sridharan, Meera

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9363-9365

10.1182/blood-2022-168232 Get It

Genomic Pathways Differentiating IgM-MGUS from Waldenstrom Macroglobulinemia: The Integrated microRNA and Gene Expression Landscape
Dasari, Surendra , Abeykoon, Jithma P. , Kapoor, Prashant , Reeder, Craig B. , Chanan‐Khan, Asher , Kyle, Robert A. , Novak, Anne J. , Ansell, Stephen M. , Chohan, Karan , Paludo, Jonas , Braggio, Esteban , Manske, Michelle K. , Paulus, Aneel , Ailawadhi, Sikander , Gertz, Morie A.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9242-9243

10.1182/blood-2022-167543 Get It

Day 100 Peripheral Blood Natural Killer Cell/CD14+HLA-DR- Ratio Predicts Clinical Outcomes in Lymphoma Patients Treated with Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation
Porrata, Luis F. , Inwards, David J. , Ansell, Stephen M. , Micallef, Ivana N. , Johnston, Patrick B. , Villasboas, José C. , Paludo, Jonas , Durani, Urshila , Markovic, Svetomir N.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10577-10578

10.1182/blood-2022-163724 Get It

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma
Desai, Sanjal H. , Mwangi, Raphael , Smith, Alexandra N., King, Rebecca L. , Thompson, Carrie A. , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Thompson, Carrie A , Wang, Yucai , Witzig, T.E. , Desai, Sanjal , Maurer, Matthew J. , Farooq, Umar , Cerhan, James R. , Feldman, Andrew L. , Habermann, Thomas M. , Wang, Yucai , Witzig, Thomas E.

Mayo Clinic

Hematological Oncology | October 28, 2022 | Volume: 41 | Issue: 1 | Pages: 39-49

10.1002/hon.3098 | PMID 36305717 Get It

Abstract Activated B cell (ABC) type diffuse large B cell lymphoma (DLBCL), double hit lymphoma (DHL) and double expressor lymphoma (DEL) have poor outcomes to frontline R‐CHOP but impact of these molecular features on outcomes of relapsed/refractory (R/R) disease is not well‐characterized. We evaluated the association of diagnostic cell of origin (COO), double hit and double expressor status with overall survival after first relapse in DLBCL patients who were enrolled into the Molecular Epidemiology Resource (MER) cohort. COO was available from immunohistochemistry (IHC) using Hans criteria or gene expression profiling (GEP) (Nanostring) on the diagnostic FFPE biopsy. Of 373 pts with R/R DLBCL, 278 had COO by IHC: 152 were GCB, 107 were non‐GCB. One hundred and fourty had COO by GEP: 44 were ABC, 65 were GCB and 13 were unclassifiable. Nineteen out of 163 (12%) were DHL; 30 out of 135 (22%) had DEL. COO, either by IHC (2 years OS GCB: 45% [CI 95 : 38–54] vs. non‐GCB: 44% [CI 95 :36–55], p > 0.05) or GEP (2 years OS ABC: 42% [CI 95 : 29–59] vs. GCB: 40% [CI 95 : 30–54], p > 0.05), was not associated with difference in OS. DHL (2 years OS 16 [CI 95 :6–45] vs. 45% [CI 95 : 34–59], p < 0.01) and DEL (2 years OS 33% [CI 95 : 20–56], vs. 50% [CI 95 : 41–60], p < 0.05) had lower OS than non‐DHL and non‐DEL/non‐DHL counterparts, respectively. COO by IHC or GEP was not associated with OS in R/R DLBCL while DHL and DEL were adverse prognostic markers in DLBCL at first relapse.
Exploring Gene Expression Profiles in Primary Central Nervous System Vasculitis
Hunder, Gene G. , Ansell, Stephen M. , Parisi, Joseph E., Croci, Stefania , Brown, Robert D. , Salvarani, Carlo , Paludo, Jonas , Giannini, Caterina , Huston, John , Koster, Matthew J. , Warrington, Kenneth J.

Mayo Clinic

Annals of Neurology | October 20, 2022 | Volume: 93 | Issue: 1 | Pages: 120-130

10.1002/ana.26537 | PMID 36264136 Get It

ObjectiveThis study was undertaken to explore the gene expression profile of primary central nervous system vasculitis (PCNSV).MethodsBrain specimens of 4 patients with granulomatous vasculitis (GV), 5 with lymphocytic vasculitis (LV), 4 with amyloid β‐related angiitis (ABRA), and 4 normal controls were studied. RNA‐sequencing was performed using the Illumina Hiseq‐4,000 platform and the Illumina TruSeq Total‐RNA library. Student t test and false discovery rate tests were performed for each of the differentially expressed transcripts. Ingenuity Pathway Analysis was used for the pathway expression analysis. CIBERSORT was used to estimate the abundances of different immune cell subsets in the tissues based on gene expression data.ResultsTranscripts differentially expressed between PCNSV and normal brain indicated that endosomal, mitochondrial, and ribosome dysfunction, alterations in protein synthesis, and noncoding RNAs might be involved in PCNSV. Pathway analysis revealed the activation of dendritic cell maturation and antigen processing as well as neuroinflammation in PCNSV versus normal brain, whereas oxidative phosphorylation was inhibited. CIBERSORT estimation of immune cell subsets suggested that activated NK cells, M1 macrophages, memory B cells, and follicular helper T cells were likely to be more prevalent in PCNSV samples. Naïve CD4 T cells and monocytes were mainly estimated to be present in GV and ABRA. Plasma cell and γδ T‐cell signatures were mainly found in LV and normal brain. GV showed higher levels of genes associated with macrophage activities and T cells. ABRA showed higher levels of long noncoding RNAs and miR‐616. LV showed higher levels of genes encoding immunoglobulins.InterpretationRNA sequencing confirmed PCNSV heterogeneity. ANN NEUROL 2023;93:120–130